• Molecular NameFluoxymesterone
  • SynonymAndrofluorene; Androfluorone; Fluossimesterone [DCIT]; Fluoximesterona [INN-Spanish]; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum [INN-Latin]; Fluoxymestrone; FXM
  • Weight336.447
  • Drugbank_IDDB01185
  • ACS_NO76-43-7
  • Show 3D model
  • LogP (experiment)2.83
  • LogP (predicted, AB/LogP v2.0)2.56
  • pkaN/A
  • LogD (pH=7, predicted)2.56
  • Solubility (experiment)0.0675 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.82
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors2
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds0
  • TPSA57.53
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anabolic steroid with strong androgenic properties that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
  • Absorption_value44.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPresence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver
  • Half life9.5 h
  • Excretionurine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A